PE20030603A1 - Derivados de quinolina - Google Patents
Derivados de quinolinaInfo
- Publication number
- PE20030603A1 PE20030603A1 PE2002000952A PE2002000952A PE20030603A1 PE 20030603 A1 PE20030603 A1 PE 20030603A1 PE 2002000952 A PE2002000952 A PE 2002000952A PE 2002000952 A PE2002000952 A PE 2002000952A PE 20030603 A1 PE20030603 A1 PE 20030603A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- quinolin
- methyl
- cycloalkyl
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A DERIVADOS DE QUINOLINA DE FORMULA I DONDE R1 ES -O-R4, -NR5R6; R2 ES H, ALQUILO CICLOALQUILO, ALCOXILO, HALOGENO,ENTRE OTROS; R3 ES H, ALQUILO, AMINO, ENTRE OTROS; R4 ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS; R5 Y R6 SON H, ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R5 Y R6 JUNTO A N AL QUE ESTAN UNIDOS FORMAN UN ANILLO HETEROCICLICO DE 5 A 10 MIEMBROS QUE COMPRENDE UN SEGUNDO HETEROATOMO SELECCIONADO DE N, S; A1 ES UN ANILLO HETEROCICLICO DE 5 A 7 MIEMBROS QUE COMPRENDE EL NITROGENO QUE ESTA UNIDO AL ANILLO DE QUINOLONA Y UN SEGUNDO HETEROATOMO O, S, N; A2 ES -CH2-, -C(O). SON COMPUESTOS PREFERIDOS (4-AZEPAN-1-IL-2-METIL-QUINOLIN-7-IL)-METANOL, 4-(2-METIL-4-PIRROLIDIN-1-IL-QUINOLIN-7-ILMETOXI)-BENZONITRILO, 4-(4-AZEPAN-1-IL-2-METIL-QUINOLIN-7-ILMETOXI)-BENZONITRILO, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON LIGANDOS DEL RECEPTOR DEL NEUROPEPTIDO Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDADES CARDIOVASCULARES, DIABETES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01123496 | 2001-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030603A1 true PE20030603A1 (es) | 2003-07-12 |
Family
ID=8178804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000952A PE20030603A1 (es) | 2001-09-28 | 2002-09-26 | Derivados de quinolina |
Country Status (24)
Country | Link |
---|---|
US (4) | US6787558B2 (es) |
EP (1) | EP1432421A1 (es) |
JP (1) | JP4187652B2 (es) |
KR (1) | KR100605765B1 (es) |
CN (1) | CN1289087C (es) |
AR (1) | AR040626A1 (es) |
AU (1) | AU2002342735B2 (es) |
BR (1) | BR0212929A (es) |
CA (1) | CA2460865C (es) |
GT (1) | GT200200197A (es) |
HK (1) | HK1074176A1 (es) |
HR (1) | HRP20040272A2 (es) |
HU (1) | HUP0401481A2 (es) |
IL (1) | IL160750A0 (es) |
MX (1) | MXPA04002825A (es) |
NO (1) | NO20041235L (es) |
NZ (1) | NZ531517A (es) |
PA (1) | PA8555401A1 (es) |
PE (1) | PE20030603A1 (es) |
PL (1) | PL370414A1 (es) |
RU (1) | RU2300531C2 (es) |
UY (1) | UY27462A1 (es) |
WO (1) | WO2003028726A1 (es) |
ZA (1) | ZA200402359B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
MX2009012390A (es) * | 2007-05-17 | 2010-06-23 | Helperby Therapeutics Ltd | Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes. |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2009209295A1 (en) * | 2008-01-28 | 2009-08-06 | Janssen Pharmaceutica Nv | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE) |
AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
BR122021002201A8 (pt) | 2011-02-25 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença |
KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9212144B2 (en) * | 2014-01-10 | 2015-12-15 | Northwestern University | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition |
US9663468B2 (en) | 2014-01-10 | 2017-05-30 | Northwestern University | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition |
DK3452465T3 (da) * | 2016-05-04 | 2021-02-08 | Genoscience Pharma | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020160151A1 (en) * | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
WO2020231739A2 (en) * | 2019-05-10 | 2020-11-19 | Antidote Ip Holdings, Llc | Compounds and methods for treating cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272824A (en) | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
US4035367A (en) | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
ES2351684T3 (es) | 1996-10-01 | 2011-02-09 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
US6199042B1 (en) * | 1998-06-19 | 2001-03-06 | L&H Applications Usa, Inc. | Reading system |
CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
ES2217797T3 (es) | 1998-08-14 | 2004-11-01 | F. Hoffmann-La Roche Ag | Vinileteres heterociclicos contra trastornos neurologicos. |
CZ20021086A3 (cs) | 1999-09-30 | 2002-10-16 | Neurogen Corporation | Alkylendiaminem substituované heterocykly |
US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
-
2002
- 2002-09-19 US US10/247,009 patent/US6787558B2/en not_active Expired - Fee Related
- 2002-09-20 CA CA002460865A patent/CA2460865C/en not_active Expired - Fee Related
- 2002-09-20 PL PL02370414A patent/PL370414A1/xx not_active Application Discontinuation
- 2002-09-20 BR BR0212929-9A patent/BR0212929A/pt not_active IP Right Cessation
- 2002-09-20 CN CNB028191919A patent/CN1289087C/zh not_active Expired - Fee Related
- 2002-09-20 EP EP02779399A patent/EP1432421A1/en not_active Withdrawn
- 2002-09-20 AU AU2002342735A patent/AU2002342735B2/en not_active Ceased
- 2002-09-20 MX MXPA04002825A patent/MXPA04002825A/es active IP Right Grant
- 2002-09-20 HU HU0401481A patent/HUP0401481A2/hu unknown
- 2002-09-20 WO PCT/EP2002/010618 patent/WO2003028726A1/en active IP Right Grant
- 2002-09-20 KR KR1020047004591A patent/KR100605765B1/ko not_active IP Right Cessation
- 2002-09-20 IL IL16075002A patent/IL160750A0/xx unknown
- 2002-09-20 RU RU2004113207/04A patent/RU2300531C2/ru not_active IP Right Cessation
- 2002-09-20 JP JP2003532058A patent/JP4187652B2/ja not_active Expired - Fee Related
- 2002-09-20 NZ NZ531517A patent/NZ531517A/en unknown
- 2002-09-25 PA PA20028555401A patent/PA8555401A1/es unknown
- 2002-09-26 PE PE2002000952A patent/PE20030603A1/es not_active Application Discontinuation
- 2002-09-27 UY UY27462A patent/UY27462A1/es not_active Application Discontinuation
- 2002-09-27 AR AR20020103663A patent/AR040626A1/es not_active Application Discontinuation
- 2002-09-27 GT GT200200197A patent/GT200200197A/es unknown
-
2004
- 2004-03-19 HR HR20040272A patent/HRP20040272A2/hr not_active Application Discontinuation
- 2004-03-24 NO NO20041235A patent/NO20041235L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402359A patent/ZA200402359B/en unknown
- 2004-07-22 US US10/896,445 patent/US7012073B2/en not_active Expired - Fee Related
-
2005
- 2005-09-21 HK HK05108269A patent/HK1074176A1/xx not_active IP Right Cessation
- 2005-11-10 US US11/272,207 patent/US7064134B2/en not_active Expired - Fee Related
-
2006
- 2006-03-16 US US11/376,976 patent/US7166589B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030603A1 (es) | Derivados de quinolina | |
PE20221283A1 (es) | Compuestos triciclicos sustituidos | |
PE20040120A1 (es) | Derivados de quinolina como antagonistas de npy | |
PE20041040A1 (es) | Compuestos derivados de amidas como inhibidores de 11-beta-hidroxiesteroide-deshidroxigenasa de tipo 1 | |
AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
PE20040832A1 (es) | Derivados de indolil pirazinona | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
AR037682A1 (es) | Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas | |
PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
CO5611110A2 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos | |
PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
PE20051171A1 (es) | Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo | |
PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
CO5021135A1 (es) | Compuestos quimicos | |
PE20030385A1 (es) | Compuestos de urea como antagonistas de receptores y5 del neuropeptido y | |
PE20080842A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
DK1778677T3 (da) | Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler | |
NI200300053A (es) | Derivados del tropano utiles en terapia. | |
PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |